{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:26:12Z","timestamp":1787617572355,"version":"build-2736575974"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Eli Lilly Japan K.K."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Erythrodermic and generalized pustular psoriasis are rare, difficult to treat forms of psoriasis. In previous reports, we documented 24\u2010 and 52\u2010week findings of an open\u2010label, phase 3 trial (<jats:styled-content style=\"fixed-case\">UNCOVER<\/jats:styled-content>\u2010J) of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis; most patients responded to treatment and maintained response through 52\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the long\u2010term (&gt;3\u00a0years) efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>These subgroup analyses were of a partial population of patients from <jats:styled-content style=\"fixed-case\">UNCOVER<\/jats:styled-content>\u2010J (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01624233; Sponsored by Eli Lilly and Company), specifically those with erythrodermic psoriasis (<jats:italic>N<\/jats:italic>\u00a0=\u00a08) or generalized pustular psoriasis (<jats:italic>N<\/jats:italic>\u00a0=\u00a05). These patients received 160\u00a0mg ixekizumab at Week 0, ixekizumab 80\u00a0mg every 2\u00a0weeks through Week 12, and ixekizumab 80\u00a0mg every 4\u00a0weeks thereafter up to Week 244. This regimen is consistent with the regimen approved in Japan for plaque, erythrodermic, and generalized pustular psoriasis and psoriatic arthritis. Efficacy assessments included Global Improvement Score (<jats:styled-content style=\"fixed-case\">GIS<\/jats:styled-content>), Psoriasis Area and Severity Index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>), dermal symptoms (for patients with generalized pustular psoriasis), Dermatology Life Quality Index (<jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>) and Itch Numeric Rating Scale (<jats:styled-content style=\"fixed-case\">NRS<\/jats:styled-content>). Safety assessments included treatment\u2010emergent adverse events and adverse events of special interest.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most patients had a <jats:styled-content style=\"fixed-case\">GIS<\/jats:styled-content> of resolved or improved from Week 12 onwards, and all patients had early and sustained improvement in <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> and dermal symptom (generalized pustular psoriasis only) scores. Mean improvements in <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> and Itch <jats:styled-content style=\"fixed-case\">NRS<\/jats:styled-content> at Week 12 were sustained through Week 244. Ixekizumab was well tolerated over 3\u00a0years of treatment in patients with erythrodermic psoriasis or generalized pustular psoriasis, and no new safety concerns were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings suggest that ixekizumab can be an effective long\u2010term treatment option for erythrodermic or generalized pustular psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.15287","type":"journal-article","created":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T10:04:50Z","timestamp":1539511490000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Long\u2010term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open\u2010label, phase 3 study (<scp>UNCOVER<\/scp>\u2010J)"],"prefix":"10.1111","volume":"33","author":[{"given":"Y.","family":"Okubo","sequence":"first","affiliation":[{"name":"Department of Dermatology Tokyo Medical University Shinjuku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mabuchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tokai University School of Medicine Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Iwatsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Elmaraghy","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Torisu\u2010Itakura","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Morisaki","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nakajo","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14105"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12773"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15292"},{"key":"e_1_2_7_12_1","first-page":"815","article-title":"Practice guidelines for generalized pustular psoriasis (GPP): treatment guidelines incorporating TNF\u2010\u03b1 inhibitor","volume":"120","author":"Iwatsuki K","year":"2010","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1246"},{"key":"e_1_2_7_15_1","first-page":"2211","article-title":"Guidelines for treatment of generalized pustular psoriasis (2014 edition)","volume":"125","author":"Terui T","year":"2015","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.15287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:50:59Z","timestamp":1694717459000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/jdv.15287"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15287","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"assertion":[{"value":"2018-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}